Caribou Biosciences, Inc.
About Caribou Biosciences, Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $11.2M
- Net income
- -$148.1M
- Total assets
- $175.4M
- Market cap
- $190.4M
- Operating margin
- -1329.4%
- Net margin
- -1327.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $11.2M
- Operating expenses
- $159.5M
- Operating income
- -$148.3M
- Income tax
- -$550.0K
- Net income
- -$148.1M
- EPS (basic)
- $-1.59
- EPS (diluted)
- $-1.59
Balance sheet
- Total assets
- $175.4M
- Current assets
- $145.2M
- Total liabilities
- $53.2M
- Current liabilities
- $25.4M
- Shareholders’ equity
- $122.2M
Cash flow
- Operating cash flow
- -$111.0M
- Investing cash flow
- $102.2M
- Financing cash flow
- $4.8M
- Net cash flow
- -$3.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $190.4M
- EPS (diluted)
- $-1.59
- Shares outstanding
- 103.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $148.1M in FY2025.
- Revenue grew 16% from FY2021 to FY2025.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Caribou Biosciences, Inc..
Write a review
News about Caribou Biosciences, Inc.
News & sentiment via Polygon.io
